IONTAS Identifies Novel SARS-CoV-2 Neutralizing Antibodies
IONTAS and FairJourney Biologics have announced the identification of neutralizing antibodies, which bind to multiple emerging SARS-CoV-2 variants.
March 26, 2021
by americanpharmaceuticalreview
Iontas and Fair Journey Biologics Partner with Quell Therapeutics
Novel target binders from Iontas/FJB will be used to uncover functional antibodies to advance Quell’s engineered Treg cell therapy pipeline.
March 10, 2021
by contractpharma
FairJourney Biologics, IONTAS enter antibody discovery pact with Pandion Therapeutics
Diverse panel of novel target binders from FairJourney Biologics and IONTAS will be used to uncover functional antibodies to advance autoimmune and inflammatory disease research.
November 24, 2020
by expresspharma
Iontas Enters Licensing Agreement with Bristol Myers Squibb
Iontas Limited, a biotechnology company focused on antibody discovery and technology development, has entered into a licensing agreement with Bristol Myers Squibb Company regarding the company’s proprietary mammalian display.
October 16, 2020
by contractpharma
IONTAS and FairJourney Biologics find COVID-19 neutralizing antibodies with picomolar potency
This viral neutralization efficiency was independently verified by the National Institute for Biological Standards and Control.
September 30, 2020
by expresspharma
FairJourney Biologics Joins Forces with Iontas
FairJourney Biologics and Iontas, two Clinical Research Organizations (CROs) in antibody discovery services, have combined their operations to create an international platform and provide their industry leading services to global biopharma.
May 14, 2020
by contractpharma
IONTAS, Teva Enter Antibody Optimization Agreement
Partnership includes options for the screening of biophysical properties suitable for developable antibodies.
July 30, 2019
by contractpharma